Mylan Pharmaceuticals Inc. obtained regulatory approval for DOXEPIN HYDROCHLORIDE, deviating from the generic terminology to highlight the brand value associated with the specific market entry. This approval expands competition in the oral antidepressant sector, potentially pressuring pricing benchmarks for the MYLAN-53429 formulation.